Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the 6th Clinical Trials on Alzheimer’s Disease (CTAD) occurring October 24-27, 2023 in Boston, MA.
Sarah DiBartolo, PhD, Principal Scientist at Applied BioMath will present, “Systematic in Silico Analysis of Clinically Tested Drugs for Reducing Amyloid Beta (Aβ) Plaque Accumulation in Alzheimer’s Disease” within the poster group titled, Proof of Concept/Translational Research for Alzheimer Drug Development Interventions.
Recent clinical trials of Aβ antibodies established a causative relationship between plaque reduction and positive clinical and functional outcomes.
Applied BioMath developed a quantitative systems pharmacology (QSP) model calibrated to clinical data for eight investigational drugs with a range of mechanisms to analyze treatment effect and enable meaningful comparisons between potential therapeutic strategies. The model simulations better predict potential clinical benefit and provide guidance for future therapeutic development.
“QSP models can incorporate data from a range of drugs, multiple studies, and a variety of data types,” said John Burke, PhD, Co-founder, President and CEO of Applied BioMath. “Modeling and simulation approaches can enable novel insights into clinical results and provide guidance to reduce clinical failures in future studies.”
Applied BioMath was awarded a grant in 2017 by the National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer’s Disease and Dementia. Work done in part by this grant was published in Alzheimer’s and Dementia in 2021.
